Startups
The funds will be used to support the development of the company’s REMaster technology platform. In addition, Remix will now be able to advance its pipeline of RNA processing targeted therapeutics as well.
A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.
New company looks to revolutionize the biopharmaceutical manufacturing process to make cutting-edge drugs more accessible.
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
George Chen left AstraZeneca after seven years to pursue his own line of oncology and immunology R&D.
Two new companies exploded onto the scene this morning, backed by significant financing that will be used to develop treatments for a wide range of diseases.
Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now becoming a factor for biotech.
ATAI Life Sciences announced on Monday that it has launched EmpathBio, a wholly-owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder.
With $46 million in Series A financing, Cambridge, Mass.-based Q32 Bio, with a focus on healthy immune regulation, has emerged onto the scene with plans to enter its lead asset into the clinic later this year.
The new company is focused on tapping into the powers of the immune system to address numerous diseases.
PRESS RELEASES